Copyright
©The Author(s) 2025.
World J Gastroenterol. Jan 21, 2025; 31(3): 98688
Published online Jan 21, 2025. doi: 10.3748/wjg.v31.i3.98688
Published online Jan 21, 2025. doi: 10.3748/wjg.v31.i3.98688
Table 3 Comparison of disease-free survival, overall survival and chemoresistance rate in the non-diabetes mellitus, diabetes mellitus, well-controlled and poorly controlled groups, n (%)
DFS | OS | CRR | |
Non-DM group (n = 160) | 34 (21.25) | 27 (16.88) | 12 (7.50) |
DM group (n = 118) | 33 (27.97) | 23 (19.50) | 17 (14.41) |
Well-controlled group (n = 73) | 16 (21.90) | 10 (13.70) | 6 (8.22) |
Poorly controlled group (n = 45) | 17 (37.78) | 13 (28.89) | 11 (24.40) |
P value1 | 0.196 | 0.575 | 0.063 |
P value2 | 0.908 | 0.538 | 0.849 |
P value3 | 0.023a | 0.072 | 0.001a |
P value4 | 0.062 | 0.043a | 0.015a |
- Citation: Guan RY, Wu JW, Yuan ZY, Liu ZY, Liu ZZ, Xiao ZC, Li JH, Huang CZ, Wang JJ, Yao XQ. Poorly controlled type II diabetes mellitus significantly enhances postoperative chemoresistance in patients with stage III colon cancer. World J Gastroenterol 2025; 31(3): 98688
- URL: https://www.wjgnet.com/1007-9327/full/v31/i3/98688.htm
- DOI: https://dx.doi.org/10.3748/wjg.v31.i3.98688